Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.

  • Published Date:

    1999 Nov-Dec

  • Source:
    Emerg Infect Dis. 5(6):828-831.
  • Language:
    English
Filetype[PDF-94.74 KB]


Details:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 1.31 MB]
    Personal Author:
    Kellner, James D. ; Ricketson, Leah J. ; ...
    Published Date:
    July 2021
    Source:
    Emerg Infect Dis. 27(7):1867-1875
    Description:
    After the introduction of pneumococcal conjugate vaccines for children, invasive pneumococcal disease caused by Streptococcus pneumoniae serotype 4 de...
    File Type:
    Filetype[PDF - 1.31 MB]
    File Type:
    Filetype[PDF - 1.31 MB]
  2. Filetype[PDF - 271.87 KB]
    Personal Author:
    Rodenburg, Gerwin D. ; de Greeff, Sabine C. ; ...
    Published Date:
    May 2010
    Source:
    Emerg Infect Dis. 16(5):816-823.
    Description:
    In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program fo...
    File Type:
    Filetype[PDF - 271.87 KB]
    File Type:
    Filetype[PDF - 271.87 KB]
  3. Filetype[PDF - 764.84 KB]
    Personal Author:
    Hanquet, Germaine ; Kissling, Esther ; ...
    Published Date:
    Sep 2010
    Source:
    Emerg Infect Dis. 16(9):1428-1439.
    Description:
    After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disea...
    File Type:
    Filetype[PDF - 764.84 KB]
    File Type:
    Filetype[PDF - 764.84 KB]
  4. Filetype[PDF - 29.12 KB]
    Personal Author:
    Vela Coral, María Claudia ; Fonseca, Nacxiry ; ...
    Published Date:
    2001 Sep-Oct
    Source:
    Emerg Infect Dis. 7(5):832-836.
    Description:
    Pneumococcal surface protein A (PspA) elicits protection in mice against fatal bacteremia and sepsis caused by genetically diverse pneumococci and pro...
    File Type:
    Filetype[PDF - 29.12 KB]
    File Type:
    Filetype[PDF - 29.12 KB]
  5. Filetype[PDF - 569.96 KB]
    Personal Author:
    Nuorti, J. Pekka ; Whitney, Cynthia G. ;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; ...
    Published Date:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by P...
    Status:
    current
    File Type:
    Filetype[PDF - 569.96 KB]
    File Type:
    Filetype[PDF - 569.96 KB]